This is because the included patients for this study were the advanced or metastatic EGFR mutation-positive NSCLC patients enrolled in the public health insurance in Fuzhou city who used the expensive novel anti-lung cancer medicine newly covered by the insurance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.